We love to hear from our listeners. Send us a message. Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market. We discuss the implications of recent blockbuster acquisitions, strategies for managing the current funding environment for biotech, what to look for in the IPO market in the coming months, alternative financing opportunities, and what besides low...
All content for Business Of Biotech is the property of Ben Comer and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
We love to hear from our listeners. Send us a message. Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market. We discuss the implications of recent blockbuster acquisitions, strategies for managing the current funding environment for biotech, what to look for in the IPO market in the coming months, alternative financing opportunities, and what besides low...
BoB In South Florida: Daniel Teper, NAYA Therapeutics
Business Of Biotech
33 minutes
1 month ago
BoB In South Florida: Daniel Teper, NAYA Therapeutics
We love to hear from our listeners. Send us a message. In this week's episode of the Business of Biotech -- part two in a four-part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- we're speaking with Daniel Teper, an entrepreneur and most recently, founder and CEO at NAYA Therapeutics. Based in South Florida, NAYA is developing NK-engaging bifunctional antibodies and Astatine-211 radiopharmaceuticals targeting hepatocellular carcinoma. Daniel discusses the compan...
Business Of Biotech
We love to hear from our listeners. Send us a message. Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market. We discuss the implications of recent blockbuster acquisitions, strategies for managing the current funding environment for biotech, what to look for in the IPO market in the coming months, alternative financing opportunities, and what besides low...
